Hepatorenal syndrome

1 paper1 finding

Humans1

Associations

1

Empagliflozin

downin humans1

1 study

Empagliflozin lowers the risk of hepatorenal syndrome in humans (1.0% vs. 1.6%).
Humansversus dapagliflozin in matched adults with liver cirrhosis
Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation
Hepatology forum14 Apr 2026

More on Empagliflozin

Latest

2 in 12 months

Clinical and Translational Gastroenterology17 Aug

The Cirrhosis Administrative Frailty Index (CAFI) Predicts Mortality Among Hospitalized Patients with Cirrhosis

Cohort study of 642,487 peopleCirrhosis

Hepatology Forum7 Aug

Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation

Cohort study in peopleEmpagliflozin